公开(公告)号：US06800454B2

公开(公告)日：2004-10-05

申请号：US09801115

申请日：2001-03-07

申请人： Dalong Ma ,  Wenling Han ,  Yingmei Zhang ,  Quansheng Song ,  Chunhui Di ,  Jiaqiang Huang ,  Jian Tang ,  Guanghui Chen

发明人： Dalong Ma ,  Wenling Han ,  Yingmei Zhang ,  Quansheng Song ,  Chunhui Di ,  Jiaqiang Huang ,  Jian Tang ,  Guanghui Chen

IPC分类号： C07H2104

CPC分类号： C07K14/521 ,  A61K38/00

摘要： The present invention provides chemokine-like factor (CKLF) polypeptides with chemotactic and hematopoietic stimulating activities and polynucleotides encoding such polypeptides. Additionally, a method for producing such CKLF polypeptides by recombinant techniques is provided. Also provided are the antibodies and antagonists against such polypeptides. The present invention further disclose a drug compound comprising a therapeutically effective amount of such CKLF polypeptides as well as pharmaceutically acceptable excipients and carriers. Also disclosed are the uses of such CKLF polypeptides and polynucleotides in diagnostics or therapeutics to treat immunodeficiency, hematopoietic diseases and primary tumors.

摘要翻译： 本发明提供具有趋化性和造血刺激活性的趋化因子样因子（CKLF）多肽和编码这些多肽的多核苷酸。 另外，提供了通过重组技术生产这种CKLF多肽的方法。 还提供了抗这种多肽的抗体和拮抗剂。 本发明还公开了包含治疗有效量的这种CKLF多肽以及药学上可接受的赋形剂和载体的药物化合物。 还公开了这样的CKLF多肽和多核苷酸在诊断或治疗中用于治疗免疫缺陷，造血疾病和原发性肿瘤的用途。

公开(公告)号：US07365171B2

公开(公告)日：2008-04-29

申请号：US10859414

申请日：2004-06-02

申请人： Dalong Ma ,  Wenling Han ,  Yingme Zhang ,  Quansheng Song ,  Chunhui Di ,  Jiaqiang Huang ,  Jian Tang ,  Guanghui Chen

发明人： Dalong Ma ,  Wenling Han ,  Yingme Zhang ,  Quansheng Song ,  Chunhui Di ,  Jiaqiang Huang ,  Jian Tang ,  Guanghui Chen

IPC分类号： C07K14/52 ,  C07H21/04 ,  C12P21/04

CPC分类号： C07K14/521 ,  A61K38/00

摘要： The present invention provides chemokine-like factor (CKLF) polypeptides with chemotactic and hematopoietic stimulating activities and polynucleotides encoding such polypeptides. Additionally, a method for producing such CKLF polypeptides by recombinant techniques is provided. Also provided are the antibodies and antagonists against such polypeptides. The present invention further disclose a drug compound comprising a therapeutically effective amount of such CKLF polypeptides as well as pharmaceutically acceptable excipients and carriers. Also disclosed are the uses of such CKLF polypeptides and polynucleotides in diagnostics or therapeutics to treat immunodeficiency, hematopoietic diseases and primary tumors.

摘要翻译： 本发明提供具有趋化性和造血刺激活性的趋化因子样因子（CKLF）多肽和编码这些多肽的多核苷酸。 另外，提供了通过重组技术生产这种CKLF多肽的方法。 还提供了抗这种多肽的抗体和拮抗剂。 本发明还公开了包含治疗有效量的这种CKLF多肽以及药学上可接受的赋形剂和载体的药物化合物。 还公开了这样的CKLF多肽和多核苷酸在诊断或治疗中用于治疗免疫缺陷，造血疾病和原发性肿瘤的用途。

公开(公告)号：US20130040325A1

公开(公告)日：2013-02-14

申请号：US13521087

申请日：2011-01-17

申请人： Yingyu Chen ,  Dalong Ma ,  Quansheng Song ,  Yingmei Zhang ,  Huan Pan ,  Lanjun Xu

发明人： Yingyu Chen ,  Dalong Ma ,  Quansheng Song ,  Yingmei Zhang ,  Huan Pan ,  Lanjun Xu

IPC分类号： G01N33/566 ,  G01N21/64

CPC分类号： G01N33/564 ,  G01N33/6893 ,  G01N2333/4703 ,  G01N2800/52

摘要： An enzyme linked immunosorbent assay (ELISA) method and kit for detecting soluble programmed cell death 5 (PDCD5) protein are provided. The method includes the following steps: (1) contacting a sample to be tested with a solid carrier loaded with a first antibody of PDCD5 protein; (2) adding a second antibody of PDCD5 protein, which is capable to binding to a detecting label; (3) adding the detecting label and detecting the bound detecting label. The soluble PDCD5 in a biological sample from a mammal comprising human can be detected by the ELISA method and kit. The method and kit can be used for detecting the level of PDCD5 protein in plasma, serum, urine, cerebrospinal fluid and synovial fluid so that an auxiliary detection method, for diagnosis of autoimmune disease, inflammation (such as hepatitis), and tumor etc., determination of disease course, observation of therapeutic effect and prognosis and medical guidance, is provided.

摘要翻译： 提供酶联免疫吸附测定（ELISA）方法和检测可溶性程序性细胞死亡5（PDCD5）蛋白的试剂盒。 该方法包括以下步骤：（1）将待测样品与载有PDCD5蛋白的第一抗体的固体载体接触; （2）加入能够结合检测标签的PDCD5蛋白的第二抗体; （3）添加检测标签并检测绑定的检测标签。 来自包含人的哺乳动物的生物样品中的可溶性PDCD5可以通过ELISA方法和试剂盒检测。 方法和试剂盒可用于检测血浆，血清，尿液，脑脊髓液和滑液中PDCD5蛋白的水平，以便辅助检测方法，用于诊断自身免疫性疾病，炎症（如肝炎）和肿瘤等。 提供疾病进展的确定，治疗效果和预后的观察以及医疗指导。

公开(公告)号：US20110009342A1

公开(公告)日：2011-01-13

申请号：US12838039

申请日：2010-07-16

申请人： Ying Wang ,  Dalong Ma ,  Quansheng Song ,  Yingmei Zhang ,  Yaxin Lou ,  Xiaoyan Ke ,  Lin Shi ,  Yanfang Wang

发明人： Ying Wang ,  Dalong Ma ,  Quansheng Song ,  Yingmei Zhang ,  Yaxin Lou ,  Xiaoyan Ke ,  Lin Shi ,  Yanfang Wang

IPC分类号： A61K38/17 ,  A61K31/7052 ,  A61P35/00 ,  A61P39/00

CPC分类号： A61K38/1761 ,  A61K45/06 ,  A61K2300/00

摘要： The invention relates to the use of PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides in preparation of sensitizers of chemotherapeutic agents for cancers. The invention also relates to the use of PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides to protect normal or diseased tissues or organs from damage or further damage, and to pharmaceutical combinations including chemotherapeutic agents and PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides in an amount effective for sensitization. Preferably, the pharmaceutical agents are selected from antibiotic and anti-metabolic agents or any combination thereof.

摘要翻译： 本发明涉及PDCD5多肽或编码PDCD5多肽的多核苷酸在制备癌症化学治疗剂敏化剂中的应用。 本发明还涉及编码PDCD5多肽以保护正常或患病组织或器官免受损伤或进一步损伤的PDCD5多肽或多核苷酸的用途，以及包括化学治疗剂和PDCD5多肽的药物组合或编码PDCD5多肽的多核苷酸的用途 数量对敏化有效。 优选地，药剂选自抗生素和抗代谢剂或其任何组合。

公开(公告)号：US07465453B2

公开(公告)日：2008-12-16

申请号：US11810590

申请日：2007-06-06

申请人： Ying Wang ,  Yingmei Zhang ,  Wenling Han ,  Dalong Ma ,  Yanan Liu ,  Caihua Yin ,  Linjie Tian ,  Dan Li

发明人： Ying Wang ,  Yingmei Zhang ,  Wenling Han ,  Dalong Ma ,  Yanan Liu ,  Caihua Yin ,  Linjie Tian ,  Dan Li

IPC分类号： A61K38/10 ,  A61K38/16 ,  C07K14/435 ,  C07K7/08 ,  C07H21/04

CPC分类号： C07K14/521 ,  A61K38/00 ,  C07K16/18 ,  C07K2317/77

摘要： Polypeptides having an amino acid sequence of SEQ ID NO: 2, and having amino acid residues 9 to 27 of SEQ ID NO: 2 are disclosed, which are together named C-terminal polypeptides of CKLF1. Also disclosed is a pharmaceutical composition containing a therapeutically effective amount of the CKLF1 C-terminal polypeptide and pharmaceutically acceptable salts, carrier or excipient. Further disclosed are the polynucleotides encoding the C-terminal polypeptides of CKLF1, and vectors and host cells containing the polynucleotides; the in vitro assays for detecting the expression level of the polypeptide or polynucleotide in a test sample; and the monoclonal or polyclonal antibodies against the polypeptides or active fragments thereof. The polypeptides of the present invention can be pharmaceutically used for treating the HIV infection, allergic disease, allograft rejection, diseases in brain and autoimmune diseases.

摘要翻译： 公开了具有SEQ ID NO：2的氨基酸序列并且具有SEQ ID NO：2的氨基酸残基9至27的多肽，它们共同命名为CKLF1的C末端多肽。 还公开了含有治疗有效量的CKLF1 C末端多肽和药学上可接受的盐，载体或赋形剂的药物组合物。 还公开了编码CKLF1的C末端多肽的多核苷酸，以及含有多核苷酸的载体和宿主细胞; 用于检测测试样品中多肽或多核苷酸的表达水平的体外测定; 以及针对多肽或其活性片段的单克隆或多克隆抗体。 本发明的多肽可以用于治疗HIV感染，过敏性疾病，同种异体移植排斥，脑部疾病和自身免疫性疾病。

公开(公告)号：US20050124043A1

公开(公告)日：2005-06-09

申请号：US10859414

申请日：2004-06-02

申请人： Dalong Ma ,  Wenling Han ,  Yingmei Zhang ,  Quansheng Song ,  Chunhui Di ,  Jiaqiang Huang ,  Jian Tang ,  Guanghui Chen

发明人： Dalong Ma ,  Wenling Han ,  Yingmei Zhang ,  Quansheng Song ,  Chunhui Di ,  Jiaqiang Huang ,  Jian Tang ,  Guanghui Chen

IPC分类号： A61K38/00 ,  C07K14/52 ,  C12N15/19 ,  C07H21/04 ,  C12P21/02

CPC分类号： C07K14/521 ,  A61K38/00

摘要： The present invention provides chemokine-like factor (CKLF) polypeptides with chemotactic and hematopoietic stimulating activities and polynucleotides encoding such polypeptides. Additionally, a method for producing such CKLF polypeptides by recombinant techniques is provided. Also provided are the antibodies and antagonists against such polypeptides. The present invention further disclose a drug compound comprising a therapeutically effective amount of such CKLF polypeptides as well as pharmaceutically acceptable excipients and carriers. Also disclosed are the uses of such CKLF polypeptides and polynucleotides in diagnostics or therapeutics to treat immunodeficiency, hematopoietic diseases and primary tumors.

摘要翻译： 本发明提供具有趋化性和造血刺激活性的趋化因子样因子（CKLF）多肽和编码这些多肽的多核苷酸。 另外，提供了通过重组技术生产这种CKLF多肽的方法。 还提供了抗这种多肽的抗体和拮抗剂。 本发明还公开了包含治疗有效量的这种CKLF多肽以及药学上可接受的赋形剂和载体的药物化合物。 还公开了这样的CKLF多肽和多核苷酸在诊断或治疗中用于治疗免疫缺陷，造血疾病和原发性肿瘤的用途。

公开(公告)号：US20070292443A1

公开(公告)日：2007-12-20

申请号：US11810590

申请日：2007-06-06

申请人： Ying Wang ,  Yingmei Zhang ,  Wenling Han ,  Dalong Ma ,  Yanan Liu ,  Caihua Yin ,  Linjie Tian ,  Dan Li

发明人： Ying Wang ,  Yingmei Zhang ,  Wenling Han ,  Dalong Ma ,  Yanan Liu ,  Caihua Yin ,  Linjie Tian ,  Dan Li

IPC分类号： A61K39/395 ,  A61K38/17 ,  C07K16/46 ,  C07K14/16

CPC分类号： C07K14/521 ,  A61K38/00 ,  C07K16/18 ,  C07K2317/77

摘要： Polypeptides having an amino acid sequence of SEQ ID NO: 2, and having amino acid residues 9 to 27 of SEQ ID NO: 2 are disclosed, which are together named C-terminal polypeptides of CKLF1. Also disclosed is a pharmaceutical composition containing a therapeutically effective amount of the CKLF1 C-terminal polypeptide and pharmaceutically acceptable salts, carrier or excipient. Further disclosed are the polynucleotides encoding the C-terminal polypeptides of CKLF1, and vectors and host cells containing the polynucleotides; the in vitro assays for detecting the expression level of the polypeptide or polynucleotide in a test sample; and the monoclonal or polyclonal antibodies against the polypeptides or active fragments thereof. The polypeptides of the present invention can be pharmaceutically used for treating the HIV infection, allergic disease, allograft rejection, diseases in brain and autoimmune diseases.

摘要翻译： 公开了具有SEQ ID NO：2的氨基酸序列并且具有SEQ ID NO：2的氨基酸残基9至27的多肽，它们共同命名为CKLF1的C末端多肽。 还公开了含有治疗有效量的CKLF1 C末端多肽和药学上可接受的盐，载体或赋形剂的药物组合物。 还公开了编码CKLF1的C末端多肽的多核苷酸，以及含有多核苷酸的载体和宿主细胞; 用于检测测试样品中多肽或多核苷酸的表达水平的体外测定; 以及针对多肽或其活性片段的单克隆或多克隆抗体。 本发明的多肽可以用于治疗HIV感染，过敏性疾病，同种异体移植排斥，脑部疾病和自身免疫性疾病。